December 21, 2014 | Israeli bio-pharmaceutical company RedHill BioPharma entered into a license agreement with the University of Minnesota to acquire rights to a patented technology to support the development of a commercial diagnostic test for the detection of MAP bacteria. Following the news, the company’s share price rose 9 percent following the news. According to RedHill’s Crohn’s disease program, RHB-104, which is currently undergoing its first Phase III study in the US, Canada and Israel, is based on the hypothesis that the disease is caused by a MAP infection in susceptible patients. Currently, there is no currently validated, commercially available method for the detection of the presence or absence of MAP in patients suffering from Crohn’s Disease and other diseases. RedHill BioPharma was founded in 2009 and focuses on the development and acquisition of late clinical-stage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers.
Facebook comments